One India Revenue (FY25)
INR 11,000 crore
+7% YoY
One India business surpassed INR 11,000 crore for the full year, reflecting strong domestic market presence.
CIPLA
Healthcare
30 Apr 2025
Cipla Ltd — Q4 FY25
Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), North America ($221M quarterly revenue), and EMU (+16% YoY).
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Cipla delivered a solid Q4 FY25 with revenue of INR 6,730 crore (+9% YoY) and EBITDA margin of 22.8% (+150bps YoY), driven by strong performance across One India (+8% YoY), North America ($221M quarterly revenue), and EMU (+16% YoY). PAT stood at INR 1,222 crore. The company guided FY26 EBITDA margin of 23.5%-24.5%, reflecting confidence despite generic Revlimid exclusivity loss. Key growth drivers include respiratory pipeline (Advair launch in FY26, six respiratory ANDAs filed), peptide launches (two to three in FY26), and Nano Paclitaxel/Nilotinib approvals. One India chronic mix improved to 61.5%. Risk: Generic Revlimid compression could pressure U.S. revenue and margins in coming quarters.
सिप्ला ने वित्त वर्ष 2025 की चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई 6,730 करोड़ रुपये रही, जो पिछले साल से 9% ज्यादा है। मुनाफा 1,222 करोड़ रुपये रहा। कंपनी का परिचालन मुनाफा (EBITDA) 22.8% रहा, जो पिछले साल से 1.5% बेहतर है। भारत में बिक्री 8% बढ़ी, अमेरिका में 221 मिलियन डॉलर की कमाई हुई, और यूरोप-मध्य पूर्व-अफ्रीका में 16% बढ़ोतरी हुई। कंपनी को अगले साल 23.5% से 24.5% तक मुनाफा रहने की उम्मीद है। मुख्य वृद्धि सांस संबंधी दवाओं, पेप्टाइड दवाओं और कैंसर की दवाओं से होगी। भारत में पुरानी बीमारियों की दवाओं का हिस्सा 61.5% हो गया है। जोखिम: अमेरिका में रेवलिमिड जेनेरिक दवा की कीमत गिरने से आने वाले समय में कमाई और मुनाफा कम हो सकता है।
Key Numbers
North America Annual Revenue (FY25)
$934 million
All-time high
North America achieved record annual revenue of $934 million, propelled by differentiated portfolio and base business.
Albuterol Market Share
18%
Steady
Albuterol market share remained steady at 18%, indicating stable demand in the U.S. respiratory market.
Chronic Mix (India)
61.5%
+8pp YoY
Chronic mix improved to 61.5% as per IQVIA MAC 25, driven by respiratory, cardiac, and urology therapies.
What Changed vs Last Quarter
NEW
Two to three peptide launches in FY26
Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
NEW
U.S. revenue run rate of ~$220 million for Q1 FY26
Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.
UPDATED
FY26 EBITDA margin guidance of 23.5%-24.5%
Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss.
UPDATED
Advair launch expected in FY26
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
DROPPED
FY26 top-line growth guidance retained
Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization.
NEW RISK
Generic Revlimid exclusivity loss
Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
NEW RISK
Lanreotide supply normalization uncertainty
While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.
NEW RISK
U.S. tariff and regulatory risks
Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.
NEW RISK
Execution risk on peptide and respiratory pipeline
Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory.
RISK GONE
Regulatory delays at Bengaluru and MDI facilities
US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.
RISK GONE
Lanreotide supply disruption recovery timeline
Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.
RISK GONE
US tariff policy uncertainty
Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.
RISK GONE
Generic Revlimid revenue decline
Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q2 FY25, Q3 FY24
Goa facility received Form 483 observations; classification still awaited, which could impact Abraxane launch timeline and other approvals.
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Filed generic Symbicort and one other inhalation asset; second site transfer to be added before approval.
Mentioned in Q3 FY24, Q3 FY25, Q4 FY24
Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26).
Mentioned in Q1 FY24, Q2 FY24
Albuterol share is dependent on which variant the market buys; recovery to prior highs is not fully in Cipla's control.
Mentioned in Q1 FY24, Q3 FY24
Goa facility due for re-inspection; delay or adverse outcome could further delay Abraxane launch.
Management Guidance
FY26 EBITDA margin guidance of 23.5%-24.5%
Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss.
Management guidance marginsAdvair launch expected in FY26
Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization.
Management guidance growthTwo to three peptide launches in FY26
Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset.
Management guidance growthU.S. revenue run rate of ~$220 million for Q1 FY26
Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.
Management guidance revenueKey Risks
Generic Revlimid exclusivity loss
Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.
high · management_commentaryLanreotide supply normalization uncertainty
While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.
medium · analyst_questionU.S. tariff and regulatory risks
Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.
medium · analyst_questionExecution risk on peptide and respiratory pipeline
Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory.
medium · data_observationNotable Quotes
Our One India business surpassed the landmark of INR 11,000 crore revenues, reflecting our strength in the domestic market.
Our leading inhalation brand became the first brand in the history of IPM to cross INR 9,000,000,000 crore reaffirming its position as a market leader.
Our outlook for projected EBITDA margin is in the range of about 23.5%-24.5%.
Frequently Asked Questions
What was Cipla's revenue in Q4 FY25?
Cipla reported revenue of ₹6,730 Cr in Q4 FY25, representing a +9% change compared to the same quarter last year.
What guidance did Cipla management give for FY26?
FY26 EBITDA margin guidance of 23.5%-24.5%: Management guided EBITDA margin in the range of 23.5%-24.5% for FY26, reflecting confidence despite Revlimid exclusivity loss. Advair launch expected in FY26: Advair will be commercialized from the U.S. facility, with launch expected in FY26 depending on FDA prioritization. Two to three peptide launches in FY26: Cipla aims to launch two to three peptide assets in FY26, with one expected to be a large asset. U.S. revenue run rate of ~$220 million for Q1 FY26: Management indicated U.S. revenue for the next quarter is expected to be around $220 million, factoring in Revlimid compression.
What are the key risks for Cipla in FY26?
Key risks include Generic Revlimid exclusivity loss — Revlimid exclusivity ends in FY26, which will compress revenue and margins in the U.S. business.; Lanreotide supply normalization uncertainty — While supplies are resuming, the timeline to regain previous market share is uncertain and may take time.; U.S. tariff and regulatory risks — Potential U.S. tariffs on pharma imports and executive orders on pricing could impact the business, though management sees limited near-term impact.; Execution risk on peptide and respiratory pipeline — Delays in approvals or commercial launches of key pipeline assets (peptides, Advair) could affect growth trajectory..
Did Cipla meet its previous quarter's guidance?
Of 2 tracked promises, management 0 met, 0 close, 2 missed.
Where can I read the full Cipla Q4 FY25 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.